Risk of recurrent high-grade cervical intraepithelial neoplasia after successful treatment: A long-term multi-cohort study

The Lancet Oncology

Volumn 12, Issue 5, 2011, Pages 441-450

  Kocken, Mariëlle ^a,b   Helmerhorst, Theo J M ^a   Berkhof, Johannes ^b   Louwers, Jacqueline A ^b   Nobbenhuis, Mariëlle A E ^a,c   Bais, Aagje G ^a   Hogewoning, Cornelis J A ^d   Zaal, Afra ^e   Verheijen, René H M ^e   Snijders, Peter J F ^b   Meijer, Chris J L M ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ROYAL MARSDEN HOSPITAL   (United Kingdom)

^d ALBERT SCHWEITZER HOSPITAL   (Netherlands)

^e UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ALGORITHM; ARTICLE; CANCER GRADING; CANCER RECURRENCE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; NETHERLANDS; PATIENT IDENTIFICATION; PRIORITY JOURNAL; RECURRENCE RISK; RISK ASSESSMENT; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; WART VIRUS;

ADULT; AGED; ALGORITHMS; ALPHAPAPILLOMAVIRUS; CERVICAL INTRAEPITHELIAL NEOPLASIA; COHORT STUDIES; CONFOUNDING FACTORS (EPIDEMIOLOGY); FEMALE; HUMANS; MASS SCREENING; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PAPILLOMAVIRUS INFECTIONS; POPULATION SURVEILLANCE; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TUMOR VIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 79955430493     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(11)70078-X     Document Type: Article

References (36)

1. National Guideline "Cervical Intraepithelial Neoplasia" [in Dutch] NvOG, (accessed Oct 20, 2010). http://www.oncoline.nl/richtlijn/item/pagina.php?richtlijn_id=220.
2. Martin-Hirsch PP, Paraskevaidis E, Bryant A, Dickinson HO, Keep SL Surgery for cervical intraepithelial neoplasia. Cochrane Database Syst Rev 2010, 6. CD001318.
3. Zielinski GD, Bais AG, Helmerhorst TJ, et al. HPV testing and monitoring of women after treatment of CIN 3: review of the literature and meta-analysis. Obstet Gynecol Surv 2004, 59:543-553.
4. Melnikow J, McGahan C, Sawaya GF, Ehlen T, Coldman A Cervical intraepithelial neoplasia outcomes after treatment: long-term follow-up from the British Columbia Cohort Study. J Natl Cancer Inst 2009, 101:721-728.
5. Soutter WP, Sasieni P, Panoskaltsis T Long-term risk of invasive cervical cancer after treatment of squamous cervical intraepithelial neoplasia. Int J Cancer 2006, 118:2048-2055.
6. Kreimer AR, Guido RS, Solomon D, et al. Human papillomavirus testing following loop electrosurgical excision procedure identifies women at risk for posttreatment cervical intraepithelial neoplasia grade 2 or 3 disease. Cancer Epidemiol Biomarkers Prev 2006, 15:908-914.
7. Paraskevaidis E, Arbyn M, Sotiriadis A, et al. The role of HPV DNA testing in the follow-up period after treatment for CIN: a systematic review of the literature. Cancer Treat Rev 2004, 30:205-211.
8. Prato B, Ghelardi A, Gadducci A, et al. Correlation of recurrence rates and times with posttreatment human papillomavirus status in patients treated with loop electrosurgical excision procedure conization for cervical squamous intraepithelial lesions. Int J Gynecol Cancer 2008, 18:90-94.
9. Colposcopy and programme management: guidelines for the NHS cervical screening programme (second edition). NHSCSP Publication No 20 NHS, (accessed Oct 20, 2010). http://www.cancerscreening.nhs.uk/cervical/publications/nhscsp20.pdf.
10. Wright TC, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D 2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ. Am J Obstet Gynecol 2007, 197:340-345.
11. Kyrgiou M, Tsoumpou I, Vrekoussis T, et al. The up-to-date evidence on colposcopy practice and treatment of cervical intraepithelial neoplasia: the Cochrane colposcopy & cervical cytopathology collaborative group (C5 group) approach. Cancer Treat Rev 2006, 32:516-523.
12. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999, 189:12-19.
13. Nobbenhuis MA, Meijer CJ, van den Brule AJ, et al. Addition of high-risk HPV testing improves the current guidelines on follow-up after treatment for cervical intraepithelial neoplasia. Br J Cancer 2001, 84:796-801.
14. Elfgren K, Jacobs M, Walboomers JM, Meijer CJ, Dillner J Rate of human papillomavirus clearance after treatment of cervical intraepithelial neoplasia. Obstet Gynecol 2002, 100:965-971.
15. Alonso I, Torne A, Puig-Tintore LM, et al. Pre- and post-conization high-risk HPV testing predicts residual/recurrent disease in patients treated for CIN 2-3. Gynecol Oncol 2006, 103:631-636.
16. Kitchener HC, Walker PG, Nelson L, et al. HPV testing as an adjunct to cytology in the follow up of women treated for cervical intraepithelial neoplasia. BJOG 2008, 115:1001-1007.
17. Bais AG, Eijkemans MJ, Rebolj M, et al. Post-treatment CIN: randomised clinical trial using hrHPV testing for prediction of residual/recurrent disease. Int J Cancer 2009, 124:889-895.
18. Coupe VM, Berkhof J, Verheijen RH, Meijer CJ Cost-effectiveness of human papillomavirus testing after treatment for cervical intraepithelial neoplasia. BJOG 2007, 114:416-424.
19. Strander B, Andersson-Ellstrom A, Milsom I, Sparen P Long term risk of invasive cancer after treatment for cervical intraepithelial neoplasia grade 3: population based cohort study. BMJ 2007, 335:1077.
20. Hogewoning CJ, Bleeker MC, van den Brule AJ, et al. Condom use promotes regression of cervical intraepithelial neoplasia and clearance of human papillomavirus: a randomized clinical trial. Int J Cancer 2003, 107:811-816.
21. Brink AA, Meijer CJ, Wiegerinck MA, et al. High concordance of results of testing for human papillomavirus in cervicovaginal samples collected by two methods, with comparison of a novel self-sampling device to a conventional endocervical brush. J Clin Microbiol 2006, 44:2518-2523.
22. Petignat P, Faltin DL, Bruchim I, Tramer MR, Franco EL, Coutlee F Are self-collected samples comparable to physician-collected cervical specimens for human papillomavirus DNA testing? A systematic review and meta-analysis. Gynecol Oncol 2007, 105:530-535.
23. Bulk S, van Kemenade FJ, Rozendaal L, Meijer CJ The Dutch CISOE-A framework for cytology reporting increases efficacy of screening upon standardisation since 1996. J Clin Pathol 2004, 57:388-393.
24. van den Brule AJ, Pol R, Fransen-Daalmeijer N, Schouls LM, Meijer CJ, Snijders PJ GP5+/6+ PCR followed by reverse line blot analysis enables rapid and high-throughput identification of human papillomavirus genotypes. J Clin Microbiol 2002, 40:779-787.
25. Snijders PJ, van den Brule AJ, Jacobs MV, Pol RP, Meijer CJ HPV DNA detection and typing in cervical scrapes. Methods Mol Med 2005, 119:101-114.
26. Wright TC Precancerous lesions of the cervix. Blaustein's pathology of the female genital tract 1995, 248-257. Springer Verlag, New York. 4th edn. K. RJ (Ed.).
27. Turnbull B The empirical distribution function with arbitrarily grouped, censored and truncated data. J R Stat Soc Series B 1976, 38:290-295.
28. Sun JG A non-parametric test for interval-censored failure time data with application to AIDS studies. Stat Med 1996, 15:1387-1395.
29. Fay MP, Shaw PA Exact and asymptotic weighted logrank tests for interval censored data: the interval R package. J Stat Softw 2010, 36:1-34.
30. R: a language and environment for statistical computing 2010, R Development Core team, R Foundation for Statistical Computing, Vienna, Austria.
31. Chan BK, Melnikow J, Slee CA, Arellanes R, Sawaya GF Posttreatment human papillomavirus testing for recurrent cervical intraepithelial neoplasia: a systematic review. Am J Obstet Gynecol 2009, 200:422e1-422e9.
32. Arbyn M, Paraskevaidis E, Martin-Hirsch P, Prendiville W, Dillner J Clinical utility of HPV-DNA detection: triage of minor cervical lesions, follow-up of women treated for high-grade CIN: an update of pooled evidence. Gynecol Oncol 2005, 99(3 suppl 1):S7-11.
33. Arbyn M, Sasieni P, Meijer CJ, Clavel C, Koliopoulos G, Dillner J Chapter 9: clinical applications of HPV testing: a summary of meta-analyses. Vaccine 2006, 24(suppl 3):78-89. S3/.
34. Bulkmans N, Berkhof J, Rozendaal L, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 2007, 370:1764-1772.
35. Strander B, Ryd W, Wallin KL, et al. Does HPV-status 6-12 months after treatment of high grade dysplasia in the uterine cervix predict long term recurrence?. Eur J Cancer 2007, 43:1849-1855.
36. Castle PE, Sideri M, Jeronimo J, Solomon D, Schiffman M Risk assessment to guide the prevention of cervical cancer. Am J Obstet Gynecol 2007, 197:356e1-356e6.